Drug Trial Radar · NCT02694822
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Apr 2016
Primary completion
Mar 30, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) human monoclonal antibody (zalifrelimab) in participants with advanced or refractory cancer and in participants who have progressed during treatment with a programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor as their most recent therapy. The phase 1 portion of the study has been completed; it enrolled adult participants with refractory, advanced cancer in a 3+3 dose escalation cohort. The phase 2 portion consisted of 51 participants who progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).
Conditions
- Advanced Solid Cancers
- Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Interventions
ZalifrelimabDrug
An anti-CTLA-4 monoclonal antibody.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of ZalifrelimabTime frame: Up to 28 days
- Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse EventsTime frame: Up to 6 years
- Phase 1: Maximum Drug Concentration (Cmax) of ZalifrelimabTime frame: Day 1 of Cycle 1 (21 days/cycle)
- Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of ZalifrelimabTime frame: Day 1 of Cycle 1 (21 days/cycle)
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Rocky Mountain Cancer Center
Denver, Colorado
University of Miami Miller School of Medicine
Miami, Florida
Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
Ochsner Cancer Institute
New Orleans, Louisiana
Atlantic Health System/Morristown Medical Center
Morristown, New Jersey
Levine Cancer Institute
Charlotte, North Carolina
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Texas Oncology - Austin Midtown
Austin, Texas
Texas Oncology, Tyler Texas
Tyler, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.